EUCTR2004-004685-32-IT进行中（未招募）1 期
A pivotal randomized study of Lonafarnib (SCH 66336) versus placebo in the treatment of subjects with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who are platelet transfusion dependent with or without anemia.
SCHERING-PLOUGH0 个研究点目标入组 200 人开始时间: 2007年9月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-GRSchering-Plough Research Institute200
进行中（未招募）
1 期
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-CZSchering-Plough Research Institute200
进行中（未招募）
1 期
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-ATSchering-Plough Research Institute200
进行中（未招募）
不适用
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-DESchering-Plough Research Institute200
已完成
不适用
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)PER-035-02SCHERING PLOUGH RESEARCH INSTITUTE,